CYTL passes the baton in sepsis

Despite good safety data from a Phase I trial of its CY1787 monoclonal antibody for sepsis, Cytel Corp. has decided to give the product to its partner, sidestepping for now the expensive and risky sepsis race.
"I wouldn't be surprised if there were more such decisions," said Jay Kranzler, president and CEO. Fortunately, the company has enough products in its pipeline to allow it to be choosy, Kranzler told BioCentury.
Two European safety trials, in nine sepsis patients and in 12 more with allergic rhinitis, showed that the mouse MAb was well